Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose ("SAD") study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant ...

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the ...

Hyperion DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million

Net cash used in investing activities increased from $ (0.2 million) for the nine months ended September 30, 2024 to $ (65.6 million) for the nine months ended September 30, 2025, primarily as a ...

Brookfield Corporation Reports Strong Third Quarter Results

Investors, analysts and other interested parties can access Brookfield Corporation’s 2025 Third Quarter Results as well as the Shareholders’ Letter and Supplemental Information on Brookfield ...